Skip to main content
. Author manuscript; available in PMC: 2010 Mar 19.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2009 Jun 24;50(12):5522–5528. doi: 10.1167/iovs.09-3804

Figure 1.

Figure 1

Blockade of CXCR4/CXCL12 interactions with anti-CXCL12 antibody inhibits uveal melanoma chemotactic responses to liver-derived chemoattractants. Uveal melanoma cells were placed in the top chambers of 24-well transwell culture plates, and protein extracts of either human liver or human smooth muscle (40 μg/mL) were added to the bottom chambers. Top and bottom chambers were separated by a membrane with 8-μm pore size. In some experiments, anti-CXCL12 or isotype control antibody was added to the lower chamber (20 μg/mL). Twenty-four hours later, the number of melanoma cells that migrated to the bottom chamber was determined by counting the melanoma cells in 10 random HPFs using a compound microscope. Mean ± SEM. *P < 0.05; **P < 0.01.